TY - JOUR AU - Ramanujam, Meera AU - Davidson, Anne PY - 2004 DA - 2004/07/29 TI - The current status of targeting BAFF/BLyS for autoimmune diseases JO - Arthritis Res Ther SP - 197 VL - 6 IS - 5 AB - It is increasingly recognized that B cells have multiple functions that contribute to the pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate therapeutic intervention. The tumor necrosis factor-like molecule BAFF (BLyS) is a key B cell survival factor and its receptors are expressed on most peripheral B cells. Several different BAFF antagonists are under development and in early clinical trials. We review here the rationale for BAFF blockade, and its predicted mechanism of action in autoimmune diseases. SN - 1478-6354 UR - https://doi.org/10.1186/ar1222 DO - 10.1186/ar1222 ID - Ramanujam2004 ER -